Regenerative medicine has been in existence for many decades, and many therapies have received United States Food and Drug Administration (FDA) approval for wound healing and orthopedic applications. Regenerative medicine is a field that applies biological science principles to promote regeneration by delivering or replacing organs, cells, or tissues in an attempt to restore diseased and damaged tissues and whole organs. There are four main avenues of therapies in regenerative medicine: viscosupplementation, platelet-rich plasma, stem cells, and prolotherapy.   Injection of hyaluronic acid into intra-articular space can restore the viscosity and elasticity of osteoarthritic synovial fluid. HA plays an essential role in shock absorption, lubrication, and the visco-elastic nature of the synovial fluid.     Prolotherapy is the injection of a solution to rehabilitate an incompetent structure and promote sclerosis at the injection site. Prolotherapy differs from other regenerative medicine techniques because the injectate lacks a biological component. The most commonly used injectate for prolotherapy is hypertonic dextrose which causes a stimulation of the body’s inflammatory cascade.  Platelet-rich plasma releases bioactive proteins that stimulate the body’s ability to heal due to its regenerative, analgesic, and anti-inflammatory properties.      According to the International Society for Cellular Therapy, the criteria for cells to be considered mesenchymal stem cells include: Plastic adherence when maintained under standard culture. Expression of CD73, CD 90, and CD 105 and not the expression of CD11b, CD14, CD19, CD34, CD45, or HLA-DR. Ability to differentiate into osteoblasts, chondroblasts, and adipocytes in vitro .